Skip to main content
. 2020 Nov 27;3:720. doi: 10.1038/s42003-020-01441-y

Fig. 2. In vivo effect of targeting CCL2 or CCR2 in combination with anti-PD-1 immunotherapy.

Fig. 2

a Subcutaneous tumor growth in syngeneic mice injected with NA13 cells (n = 6 biologically independent mice per group). Data representative of two independent experiments. Statistical significance was determined by two-way ANOVA. Arrows indicate dates in which anti-PD-1 treatment was given. Mean ± SD. b Individual tumor volumes as a function of time. Each line represents a single mouse (n = 10 or 11 biologically independent mice per group). c Waterfall plot showing change in NA13 tumor volume on endpoint day 30 post tumor injection compared to baseline prior to treatment with and without CCR2 antagonist RS504393 and/or anti-PD-1 treatment. Starting on day 14, mice were treated daily with CCR2 antagonist RS503393, and every three days with anti-PD-1.